A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- 12 April 2013
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (7), 1067-1072
- https://doi.org/10.3324/haematol.2012.074831
Abstract
The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43–0.77], PKeywords
This publication has 15 references indexed in Scilit:
- Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelinesLeukemia Research, 2010
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Management of patients with higher risk myelodysplastic syndromesCritical Reviews in Oncology/Hematology, 2005
- Report of an international working group to standardize response criteria for myelodysplastic syndromes.2000
- International Scoring System for Evaluating Prognosis in Myelodysplastic SyndromesBlood, 1997
- DNA methylation and gene expression.1991
- A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder biasStatistics in Medicine, 1984
- Analysis of survival by tumor response.Journal of Clinical Oncology, 1983
- EFFECT OF 5-AZACYTIDINE ON DIFFERENTIATION AND DNA METHYLATION IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL-60)1983
- The effect of chemotherapy on acute leukemia in the humanJournal of Chronic Diseases, 1961